KCM
APLS

Kingdon Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Kingdon Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200,000
Closed -$13.7M – 52
2022
Q3 		$13.7M Buy
+200,000
New +$11.8M 1.75% 14
2022
Q2 		– Sell
-150,000
Closed -$7.62M – 74
2022
Q1 		$7.62M Buy
+150,000
New +$6.62M 0.79% 33
2021
Q4 		– Sell
-50,000
Closed -$1.65M – 79
2021
Q3 		$1.65M Buy
+50,000
New +$2.81M 0.2% 56

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kingdon Capital Management's APLS Position: Q4 2021 in Review

Kingdon Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2021, closing a stake of 100,000 shares — an estimated $3.3M sold.

Kingdon Capital Management first reported a position in APLS in Q3 2021 and held it in 1 quarter. The position peaked at $3.3M in Q3 2021. 186 funds tracked by Wall St. Rank hold APLS as of Q4 2021.

  • Kingdon Capital Management reported no remaining Apellis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Kingdon Capital Management sold 100,000 Apellis Pharmaceuticals shares in Q4 2021, an estimated $3.3M.
  • Kingdon Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Kingdon Capital Management's Apellis Pharmaceuticals position peaked at $3.3M in Q3 2021.
  • 186 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2021.

Based on Kingdon Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.